No deleterious effect of low dose methotrexate on titanium implant osseointegration in a rabbit model

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorCARVAS, Janaina Badin
dc.contributor.authorPEREIRA, Rosa Maria Rodrigues
dc.contributor.authorBONFA, Eloisa
dc.contributor.authorSILVEIRA, Celey Aparecida
dc.contributor.authorLIMA, Luiz Lapa
dc.contributor.authorCAPARBO, Valeria de Falco
dc.contributor.authorMELLO, Suzana Beatriz Verissimo de
dc.date.accessioned2017-11-27T16:23:21Z
dc.date.available2017-11-27T16:23:21Z
dc.date.issued2011
dc.description.abstractOBJECTIVE: To evaluate the effect of low dose methotrexate alone or in combination with glucocorticoid treatment on titanium implant osseointegration. METHODS: Groups of 6-8 adult New Zealand White rabbits were treated for 18 weeks with saline (control), methotrexate, glucocorticoid, or methotrexate plus glucocorticoid. The animals received a titanium implant in the tibia at week 6. Lumbar spine and tibia bone mineral densities were analyzed before and after treatment. Histomorphometric analysis of bone cortical thickness, total bone area around the implant, and % of bone to implant contact was performed. RESULTS: After 18 weeks, the change in the bone mineral density in the lumbar spines and tibias in the methotrexate group was comparable to the control group (0.035 vs. 0.055 g/cm(2) and 0.021 vs. 0.041 g/cm(2), respectively). In contrast, both the glucocorticoid group and glucocorticoid plus methotrexate group had significant reductions at both sites. Histomorphometric analysis of the tibia in the control and methotrexate groups revealed no significant changes in cortical thickness (133 vs. 126 mu m), total bone area around the implant (33 vs. 30%), or bone to implant contact (40 vs. 38%). In contrast, glucocorticoid group had significant reductions compared to controls in tibia cortical thickness (99 vs. 133 mu m), total bone area around the implant (24 vs. 33%), and bone to implant contact (27 vs. 40%). Similar reductions were observed in the glucocorticoid plus methotrexate group. CONCLUSIONS: Our results demonstrate that low dose methotrexate treatment does not affect titanium implant osseointegration, suggesting that this therapy is safe for surgical procedures requiring a titanium implant.
dc.description.indexMEDLINE
dc.description.sponsorshipConexao Sistema de Protese Ltda
dc.description.sponsorshipFAPESP [06/57383-5]
dc.description.sponsorshipConselho Nacional de Ciencia e Tecnologia (CNPQ) [300559/2009-7, 301411/2009-3]
dc.description.sponsorshipFederico Foundation
dc.identifier.citationCLINICS, v.66, n.6, p.1055-1059, 2011
dc.identifier.doi10.1590/S1807-59322011000600023
dc.identifier.eissn1980-5322
dc.identifier.issn1807-5932
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/22563
dc.language.isoeng
dc.publisherHOSPITAL CLINICAS, UNIV SAO PAULO
dc.relation.ispartofClinics
dc.rightsopenAccess
dc.rights.holderCopyright HOSPITAL CLINICAS, UNIV SAO PAULO
dc.subjectMethotrexate
dc.subjectOsseointegration
dc.subjectDental Implant
dc.subjectGlucocorticoid
dc.subject.otherrheumatoid-arthritis
dc.subject.otherbone response
dc.subject.otherosteopathy
dc.subject.otherosteoporosis
dc.subject.otherfracture
dc.subject.othersystem
dc.subject.otherhealth
dc.subject.otherrats
dc.subject.wosMedicine, General & Internal
dc.titleNo deleterious effect of low dose methotrexate on titanium implant osseointegration in a rabbit model
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalCARVAS, Janaina Badin:Univ Sao Paulo, Fac Med, Div Rheumatol, BR-05508 Sao Paulo, Brazil
hcfmusp.author.externalLIMA, Luiz Lapa:Univ Sao Paulo, Dent Branch, BR-05508 Sao Paulo, Brazil
hcfmusp.citation.scopus9
hcfmusp.contributor.author-fmusphcROSA MARIA RODRIGUES PEREIRA
hcfmusp.contributor.author-fmusphcELOISA SILVA DUTRA DE OLIVEIRA BONFA
hcfmusp.contributor.author-fmusphcCELEY APARECIDA EUGENIO SILVEIRA CASADIO
hcfmusp.contributor.author-fmusphcVALERIA DE FALCO CAPARBO
hcfmusp.contributor.author-fmusphcSUZANA BEATRIZ VERISSIMO DE MELLO
hcfmusp.description.beginpage1055
hcfmusp.description.endpage1059
hcfmusp.description.issue6
hcfmusp.description.volume66
hcfmusp.origemWOS
hcfmusp.origem.pubmed21808875
hcfmusp.origem.scopus2-s2.0-79961146444
hcfmusp.origem.wosWOS:000293410000023
hcfmusp.publisher.citySAO PAULO
hcfmusp.publisher.countryBRAZIL
hcfmusp.relation.referencePablos AB, 2008, J PERIODONTOL, V79, P300, DOI 10.1902/jop.2008.070301
hcfmusp.relation.referencePRESTON SJ, 1993, ANN RHEUM DIS, V52, P582, DOI 10.1136/ard.52.8.582
hcfmusp.relation.referenceMarco F, 2005, MICRON, V36, P630, DOI 10.1016/j.micron.2005.07.008
hcfmusp.relation.referenceTang BX, 2008, CLIN THER, V30, P1375, DOI 10.1016/j.clinthera.2008.07.004
hcfmusp.relation.referenceMASOUD I, 1986, J ORTHOPAED RES, V4, P221, DOI 10.1002/jor.1100040211
hcfmusp.relation.referenceMavrogenis AF, 2009, J MUSCULOSKEL NEURON, V9, P61
hcfmusp.relation.referenceEberhardt C, 2007, J ORTHOP SCI, V12, P61, DOI 10.1007/s00776-006-1081-2
hcfmusp.relation.referenceLuppen CA, 2002, J BONE MINER RES, V17, P301, DOI 10.1359/jbmr.2002.17.2.301
hcfmusp.relation.referenceMombelli A, 2006, CLIN ORAL IMPLAN RES, V17, P97, DOI 10.1111/j.1600-0501.2006.01354.x
hcfmusp.relation.referenceSakakura CE, 2007, CLIN ORAL IMPLAN RES, V18, P34, DOI 10.1111/j.1600-0501.2006.01253.x
hcfmusp.relation.referenceTakayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
hcfmusp.relation.referenceEder A, 1999, INT J ORAL MAX IMPL, V14, P587
hcfmusp.relation.referenceBasarir K, 2009, INT ORTHOP, V33, P855, DOI 10.1007/s00264-007-0490-y
hcfmusp.relation.referenceCarvas JSB, 2010, OSTEOPOROSIS INT, V21, P1723, DOI 10.1007/s00198-009-1125-5
hcfmusp.relation.referenceCranney AB, 2001, J RHEUMATOL, V28, P2395
hcfmusp.relation.referenceDressler MR, 2005, J ORTHOP RES, V23, P287, DOI 10.1016/j.orthres.2004.06.017
hcfmusp.relation.referenceELLERBE DM, 1995, OTOLARYNG CLIN N AM, V28, P365
hcfmusp.relation.referenceFujimoto T, 1998, INT J ORAL MAX IMPL, V13, P183
hcfmusp.relation.referenceHe FM, 2009, INT J ORAL MAX SURG, V38, P677, DOI 10.1016/j.ijom.2009.03.716
hcfmusp.relation.referenceMaenaut K, 1996, J RHEUMATOL, V23, P2156
hcfmusp.relation.referenceMAY KP, 1994, ARTHRITIS RHEUM, V37, P201, DOI 10.1002/art.1780370208
hcfmusp.relation.referenceMEISTER B, 1994, MED PEDIATR ONCOL, V23, P493, DOI 10.1002/mpo.2950230608
hcfmusp.relation.referenceMiedany YM, 1998, J RHEUMATOL, V25, P2083
hcfmusp.relation.referenceMottonen TT, 1999, CLIN EXP RHEUMAT S18, V6, P59
hcfmusp.relation.referenceROSENQVIST R, 1986, J BONE JOINT SURG AM, V68A, P538
hcfmusp.relation.referenceSilverman Stuart L, 2009, Curr Osteoporos Rep, V7, P23
hcfmusp.relation.referenceSøballe K, 1993, Acta Orthop Scand Suppl, V255, P1
hcfmusp.relation.referenceStrand V, 2007, AM J MANAG CARE, V9, P237
hcfmusp.relation.referenceTorikai Eiji, 2006, Mod Rheumatol, V16, P350, DOI 10.1007/s10165-006-0517-z
hcfmusp.relation.referencevan der Bijl A E, 2008, Ned Tijdschr Geneeskd, V152, P2357
hcfmusp.relation.referenceVan Leeuwen BL, 2003, CLIN ORTHOP RELAT R, P243, DOI 10.1097/01.blo.0000073348.50837.f2
hcfmusp.relation.referencevon Holst D, 1999, NATURWISSENSCHAFTEN, V86, P388, DOI 10.1007/s001140050638
hcfmusp.relation.referenceWerner S B, 1996, J Oral Implantol, V22, P216
hcfmusp.relation.referenceYoshida M, 2005, J RHEUMATOL, V32, P787
hcfmusp.relation.referenceZonneveld IM, 1996, ARCH DERMATOL, V132, P184, DOI 10.1001/archderm.132.2.184
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicationa7d269ab-50f5-415f-a84f-b03f05f2093c
relation.isAuthorOfPublication708e64de-56af-4523-b920-b237f71535b2
relation.isAuthorOfPublicationa72307c6-a507-431a-8f6e-ff9d7ea0b062
relation.isAuthorOfPublicationb0982534-03fb-47d4-aa9e-3de96e9b623c
relation.isAuthorOfPublication97daae4d-6988-4946-9b63-be2d1cb2b653
relation.isAuthorOfPublication.latestForDiscoverya7d269ab-50f5-415f-a84f-b03f05f2093c
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_CARVAS_No_deleterious_effect_of_low_dose_methotrexate_on_2011.PDF
Tamanho:
565.13 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/17